What is the recommended prenatal management when a non‑invasive prenatal test indicates the fetus may have glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?

Prenatal Management of G6PD Deficiency Detected on NIPT

G6PD deficiency detected on NIPT does not require routine prenatal intervention in most cases, but warrants careful surveillance for rare severe fetal anemia and parental counseling about neonatal management.

Initial Assessment and Risk Stratification

When NIPT suggests fetal G6PD deficiency, your first step is determining whether this represents a high-risk scenario. G6PD deficiency is mentioned as a rare cause of fetal anemia and nonimmune hydrops fetalis (NIHF) in established guidelines 1, though it accounts for only a small fraction of cases compared to alloimmunization or alpha-thalassemia.

Key historical factors to assess:

• Maternal G6PD status (carrier vs. deficient vs. normal)
• Previous pregnancies complicated by unexplained neonatal anemia or jaundice
• Maternal exposure to oxidative triggers (fava beans, certain medications, infections)
• Family history of severe G6PD-related complications

Prenatal Surveillance Strategy

Standard Management (Most Cases)

For the majority of G6PD-deficient fetuses, no specific prenatal intervention is needed beyond:

• Serial ultrasound monitoring starting at 28-30 weeks for signs of fetal anemia (middle cerebral artery peak systolic velocity measurements)
• Avoidance of maternal oxidative triggers that could cross the placenta
• Documentation for neonatal team handoff

High-Risk Scenarios Requiring Enhanced Surveillance

A systematic review identified that G6PD-related NIHF occurs rarely but can be severe 2. Enhanced monitoring is warranted when:

• Previous pregnancy with unexplained neonatal anemia (occurred in 50% of multigravida cases with G6PD-related NIHF 2)
• Maternal G6PD deficiency (not just carrier status) with oxidative exposures
• Ultrasound findings suggestive of anemia (elevated MCA-PSV, early hydrops)

In these cases, initiate weekly MCA-PSV Doppler surveillance starting at 24-26 weeks, similar to protocols for other causes of fetal anemia 1.

Diagnostic Confirmation

If fetal anemia is suspected based on MCA-PSV >1.5 MoM:

1. Cordocentesis with fetal blood sampling to confirm hemoglobin level (reference ranges by gestational age provided in 1)
2. G6PD enzyme activity testing on fetal blood sample
3. Genetic confirmation if available (though prenatal DNA testing for G6PD is technically feasible 3, it's not routinely offered in most centers)

Intervention Thresholds

Intrauterine transfusion is indicated when fetal hemoglobin falls below 0.55 MoM (severe anemia) 1. In the systematic review, 66.7% of G6PD-related NIHF cases required cordocentesis for fetal transfusion 2.

Important Caveats

• Female fetuses can be affected despite X-linked inheritance pattern (33.3% of reported G6PD-related NIHF cases were female 2)
• Mean gestational age at diagnosis in severe cases was 32.2 weeks, with delivery at 35.7 weeks 2
• Standard workup for NIHF should still be completed, as G6PD deficiency is a diagnosis of exclusion

Delivery Planning

Timing: Most affected pregnancies can proceed to term unless:

• Severe fetal anemia develops requiring delivery after 34-35 weeks
• Hydrops develops despite transfusion

Location: Deliver at a facility with:

• Immediate neonatal intensive care capability
• Ability to perform exchange transfusion if needed (33.3% of cases required immediate postnatal transfusion 2)
• Experience managing severe neonatal hyperbilirubinemia

Critical Neonatal Handoff

Document clearly for the neonatal team:

• Confirmed or suspected G6PD deficiency
• Any prenatal transfusions performed
• Maternal G6PD status
• Family history of severe complications

This is crucial because neonatal hyperbilirubinemia is the most common serious complication 4, and G6PD-deficient newborns require close bilirubin monitoring to prevent kernicterus, even without overt hemolysis.

Avoid Common Pitfalls

• Don't assume male-only disease—female fetuses with homozygous or compound heterozygous mutations can be severely affected
• Don't overlook maternal oxidative exposures during pregnancy (medications, infections, dietary triggers)
• Don't delay MCA-PSV surveillance if there's a history of unexplained neonatal anemia in prior pregnancies